Articles tagged "Induction therapy"

2020 American Transplant Congress
Comparison of Anti-Thymocyte Globulin and Alemtuzumab as Induction Therapy in Older Kidney Transplant Recipients
M. Chaung, E. Hollinger, M. Brokhof, N. Alvey, L. Lineberger, N. Kenyon
Rush University Medical Center, Chicago, IL
*Purpose: The purpose of this study is to evaluate the safety and efficacy of induction with either anti-thymocyte globulin (ATG) (total dose 5 mg/kg) or…
2020 American Transplant Congress
Low-Dose Rabbit Antithymocyte Globulin Induction in Elderly Kidney Transplant Recipients at High Immunologic Risk is Safe and May Prevent Excess Rejection
E. Sartain¹, B. Nettles¹, B. Crowther¹, P. Klem¹, K. Schwarz¹, S. Davis²
¹University of Colorado Hospital, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO
*Purpose: Patients aged ≥65 years are a growing segment of kidney transplant recipients (KTRs). Consensus on induction immunosuppression in this population is unclear given higher…
2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
M. Plazak¹, X. Gao², S. Gale², B. Reed², R. Madathil¹, S. Hammad¹, B. Ravichandran¹
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…
2020 American Transplant Congress
Pancreas Transplant in Patients Older Than 50: An Analysis of Outcomes and Immunosuppression
I. Booth¹, J. Casale¹, S. Freedman¹, B. Ravichandran¹, J. Scalea², A. Haririan², B. Masters¹
¹Pharmacy, University of Maryland Medical Center, Baltimore, MD, ²Medicine, University of Maryland Medical Center, Baltimore, MD
*Purpose: Pancreas transplant (PT) is the ideal therapy for many patients with diabetes and kidney failure. There are limited published data addressing the impact of…
2020 American Transplant Congress
Thymoglobulin (ATG) Induction vs. Campath vs. Simulect in DCD Kidneys in UK; Induction Regimes Play a Role after All
A. Asderakis¹, T. Sabbah¹, J. Watkins², L. Szabó¹, D. Elker¹, A. M. Ilham¹, E. Ablorsu¹, M. Stephens¹, U. Khalid¹, R. Chavez¹
¹Cardiff Transplant Unit,, University Hospital of Wales, Cardiff, United Kingdom, ²Infection and Immunity, Cardiff University, Cardiff, United Kingdom
*Purpose: Controlled DCD kidneys have increased dramatically in UK. They suffer from a higher rate of DGF and, often in UK, come from older donors…
2020 American Transplant Congress
Safety Outcomes in Lower-Weight vs Higher-Weight Recipients of Fixed Dose Alemtuzumab for Kidney Transplant Induction
A. Freeman, S. Anders, B. Wise, M. Janusek, L. Hutchinson, U. Kaszubski, D. Marroquin, D. Martin, H. Bohorquez
Ochsner Medical Center, New Orleans, LA
*Purpose: Alemtuzumab is a lymphocyte-depleting monoclonal antibody used for renal transplant induction, and is associated with significant leukopenia, increased infections and malignancy. Multiple dosing strategies…
2020 American Transplant Congress
Ten Year Results of a Single Center Study of Rabbit Anti-Thymocyte Globulin Compared to Alemtuzumab Induction in Simultaneous Pancreas-Kidney Transplantation
V. Gurram, K. Gurung, G. Orlando, A. Farney, J. Rogers, C. Jay, W. Doares, S. Kaczmorski, A. Reeves-Daniel, A. Mena-Gutierrez, M. Gautreaux, R. Stratta
Abdominal Transplant Surgery, Wake Forest Baptist Health, Winston Salem, NC
*Purpose: The study purpose was to analyze 10-year outcomes of depleting antibody induction agents in simultaneous pancreas-kidney transplant (SPKT) at a single center*Methods: From 2/02…
2020 American Transplant Congress
Anti-Thymocyte Globulins Induced Immunomodulatory Effect and Increased Regulatory T Cell in a In Vitro Model of Allogeneic Cell Coculture
M. Colladant¹, J. Lion², P. Saas³, S. Perruche³, D. Ducloux¹, N. Mooney², J. Bamoulid¹
¹Nephrologie, Dialyse et Transplantation, CHU de Besançon, Besancon, France, ²Equipe INSERM: Endothelium, Inflammation et Alloreactivity INSERM UMR-S 976, Paris, France, ³INSERM U1098 RIGHT, Université de Franche-Comté EFS Bourgogne Franche-Comté, Besancon, France
*Purpose: Two types of Anti-Thymocyte Globulins (ATG) are commonly used in renal transplantation (Thymoglobuline and Grafalon) and induce severe, dose-dependent and sometimes persistent CD4+ T…
2019 American Transplant Congress
Antithymocyte Globulin is Associated with Mature T Cell Phenotypes and Decreased Risk of Non-EBV Infections in Transplanted Children
B. I. Shaw¹, L. Stempora¹, C. Chan¹, R. B. Ettenger², P. C. Grimm³, H. Lee¹, E. F. Reed², M. M. Sarwal⁴, B. L. Warshaw⁵, C. Zhao¹, O. M. Martinez³, A. D. Kirk¹, E. T. Chambers¹
¹Pediatrics/Surgery, Duke University, Durham, NC, ²Pediatrics, University of California, Los Angeles, Los Angeles, CA, ³Pediatrics/Surgery, Stanford University, Palo Alto, CA, ⁴Pediatrics/Surgery, University of California, San Francisco, San Francisco, CA, ⁵Pediatrics, Emory University, Atlanta, GA
*Purpose: Depletional induction therapies are known to reduce the rate of acute rejection; yet data from the US Renal Data System have shown that use…
2019 American Transplant Congress
Induction Therapy in Elderly Kidney Transplant Recipients with Low Immunological Risk
C. Masset¹, J. Boucquemont², V. Garrigue³, M. Ladrière⁴, F. Buron⁵, E. Cassuto⁶, Y. Foucher², J. Dantal¹
¹University Hospital of Nantes, Nantes, France, ²University of Nantes, Nantes, France, ³University Hospital of Montpellier, Montpellier, France, ⁴University Hospital of Nancy, Nancy, France, ⁵University Hospital of Lyon, Lyon, France, ⁶University Hospital of Nice, Nice, France
*Purpose: Thymoglobulin (ATG) and Basiliximab (BSX) lead to similar rejection rates in low immunological risk patients. ATG seems to be associated with infectious and malignancy…

« Previous Page
1
…
7
8
9
10
11
…
31
Next Page »